Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in
Advertisement

ASLAN Pharmaceuticals Limited ASLN

Set alert

Price alert · ASLN

All alert types
0.60 0.00 0.00%

At close · Jul 18

0.60 Day range 0.6999

52-week range unavailable

Open
0.63
Prev close
0.60
Mkt cap
777.12M
Vol
769.82K
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
0.60
High
0.6999
Forward P/E
-0.03
Beta
1.40
Short ratio
1.85
Inst. own
13.21%
Dividend
0.00
Ex-div date
Earnings
Aug 9, 2024
50-d avg
1.07
200-d avg
3.48
1y target
72.00

6M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Apr 12, 2024Earnings: —; estimate 0; surprise —%
  • May 9, 2024Earnings: —; estimate -5.44; surprise —%
  • Jul 3, 2024Split: 1 for 8
  • Aug 9, 2024Earnings: —; estimate 0; surprise —%
Signals (27)
NameDateAgo
MACD: Buy SignalJul 31, 20242 years ago
MACD: Sell SignalJul 15, 20242 years ago
RSI: OversoldJul 15, 20242 years ago
MACD: Buy SignalJul 10, 20242 years ago
RSI: OversoldJul 5, 20242 years ago
RSI: OversoldJul 2, 20242 years ago
RSI: OversoldJun 24, 20242 years ago
RSI: OversoldJun 18, 20242 years ago
MACD: Sell SignalJun 11, 20242 years ago
MACD: Buy SignalMay 9, 20242 years ago
MACD: Sell SignalMay 8, 20242 years ago
MACD: Buy SignalMay 1, 20242 years ago
SMA: BearishMar 28, 20242 years ago
SMA: BearishMar 22, 20242 years ago
MACD: Sell SignalMar 19, 20242 years ago
SMA: BullishMar 18, 20242 years ago
SMA: BearishMar 14, 20242 years ago
SMA: BullishMar 13, 20242 years ago
SMA: BearishMar 12, 20242 years ago
SMA: BullishMar 11, 20242 years ago
RSI: OverboughtMar 11, 20242 years ago
SMA: BearishMar 1, 20242 years ago
SMA: BullishFeb 29, 20242 years ago
RSI: OverboughtFeb 29, 20242 years ago
SMA: BullishFeb 28, 20242 years ago
MACD: Buy SignalFeb 28, 20242 years ago
SMA: BearishFeb 16, 20242 years ago

Key statistics

Financials
Market cap
1.70M
Enterprise value
288.33M
Trailing P/E
0.00
Forward P/E
-0.03
PEG ratio
0.00
Price / sales
0.14
Price / book
0.00
EPS (TTM)
-16.00
Beta
1.40
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-291.89%
Revenue (TTM)
12.00M
Revenue growth
0.00%
Free cash flow
0
Total cash
18.40M
Total debt
26.67M
Return on equity
0.00%
Shares outstanding
2.83M
Short % of float
1.46%
50-day average
1.07
200-day average
3.48

Analyst view

Consensus: buy

Buy
Price target (mean) 72.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy2
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Aug 9, 2024

Expected Aug 9, 2024. Consensus EPS estimate -3.60.

Earnings history

Financials — quick view

All financials
ASLN Revenue — quarterly 0
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024
ASLN Net income — quarterly -9.92M
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024
ASLN EPS — quarterly -4.00
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024

Earnings

ASLN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Aug 9, 2024Jun 1, 20240.00———
May 9, 2024Mar 1, 2024-5.44———
Apr 12, 2024Dec 1, 20230.00———
Oct 27, 2023Sep 1, 2023-6.80———
Aug 11, 2023Jun 1, 2023-6.96———
Apr 28, 2023Mar 1, 2023-6.40———

Upgrades / downgrades

ASLN analyst upgrades and downgrades
DateFirmActionFromTo
Aug 13, 2023HC Wainwright & Co.reitBuyBuy
Aug 13, 2023Roth MKMreitBuyBuy
Jul 6, 2023HC Wainwright & Co.reitBuyBuy
Jun 25, 2023HC Wainwright & Co.reitBuyBuy
Jun 22, 2023HC Wainwright & Co.reitBuyBuy
May 30, 2023Roth MKMinit—Buy

About ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Sector
Healthcare
Industry
Biotechnology
Country
Singapore
Website
aslanpharma.com

News

All news

Your note

Sign in to keep a note on ASLN — it syncs with the Stock Master app.

Institution ownership

ASLN institution ownership
Holder% heldSharesValueReported
Vivo Capital, LLC37.39%2,840,90810.37MJun 29, 2023
Tang Capital Management, LLC14.85%1,128,0684.12MJun 29, 2023
BVF Inc.13.82%1,049,9993.83MJun 29, 2023
Parkman Healthcare Partners LLC6.67%506,6211.85MJun 29, 2023
Temasek Holdings (Private) Limited4.42%335,6151.22MJun 29, 2023
Sio Capital Management, LLC3.34%254,150927.65KJun 29, 2023

Fund ownership

ASLN fund ownership
Holder% heldSharesValueReported
SPDR Portfolio Emerging Markets ETF0.13%9,90821.05KAug 30, 2023
Fidelity NASDAQ Composite Index Fund0.10%7,96831.87KMay 30, 2023

Splits

ASLN stock splits
DateRatio
Jul 3, 20241:8
Mar 13, 20231:5
Advertisement